secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monte Rosa Therapeutics, Inc. (GLUE)
CIK:        0001826457
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0000950170-24-056253
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Monte Rosa Q1 net loss $32M; pipeline advances with MRT-2359, MRT-6160, MRT-8102 milestones
--------------------------------------------------------------------------------

- Q1 2024 net loss $32.0M; cash $197.8M (down from $237.0M Dec 2023), sufficient into H1 2026.
- MRT-2359: RP2D determination expected Q2 2024, Phase 1 clinical data H2 2024, Phase 2 before year-end.
- MRT-6160: IND submission Q2 2024, Phase 1 SAD/MAD study mid-2024, data Q1 2025; favorable GLP tox profile.
- MRT-8102: NEK7-directed MGD shows CNS exposure in NHPs; IND on track for Q1 2025.
- New CCNE1-directed MGD discovery program launched for previously undruggable oncology target.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826457/000095017024056253/0000950170-24-056253-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826457/000095017024056253/glue-20240509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-056253

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer